EMUNO Therapeutics Achieves Significant R&D Milestones with Enamine's IDD Platform

EMUNO Therapeutics successfully reached critical R&D milestones in its immuno-oncology small molecule programs, enabled by a comprehensive collaboration with Enamine's Integrated Drug Discovery (IDD) Platform. This partnership, initiated in June 2025, leverages Enamine's expertise in drug design, chemistry, and biology, alongside AI/ML approaches, to efficiently advance EMUNO's pipeline. Their joint effort, including the EU-supported EMT-224 candidate for solid tumors, aims to deliver clinical impact for challenging malignancies with remarkable speed and precision.

EMUNO Therapeutics, a pharmaceutical startup focused on modulating immune responses, has announced significant R&D milestones achieved through its collaboration with Enamine, a leading Contract Research Organisation. The partnership, which began in June 2025, centers on advancing EMUNO’s small molecule programs in immuno-oncology, targeting challenging malignancies and autoimmune disorders. A key initiative, the IMMUNOCON project, supported by an EIC Transition Grant from the European Innovation Council, is progressing the drug candidate EMT-224 towards clinical readiness to address refractory solid tumors.Enamine's Integrated Drug Discovery (IDD) Platform played a crucial role, providing expertise in Computer-aided Drug Design (CADD), AI/ML, innovative medicinal chemistry, and preclinical biology. This platform, including capabilities like structure-based drug design, fragment-based approaches (UFrag™), and access to Enamine's vast REAL compounds library, facilitated highly efficient design-make-test-analyze cycles. EMUNO's CEO, Dr. Emilia Neuwirt, lauded Enamine's comprehensive support and operational excellence, while Enamine's Vice President of Partnerships, Sven Wagner, expressed honor in the ongoing collaboration, highlighting EMUNO's profound competence. Both companies emphasized the productive nature of their joint efforts, setting ambitious goals for future drug discovery to deliver real impact for patients. The collaboration showcases a successful biotech-CRO model for accelerating therapeutic development.